A Review of the Use of Chemoprotectants in Cancer Chemotherapy
Author:
- 1 September 1994
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 11 (3) , 153-162
Abstract
Dose-limiting toxicity secondary to antineoplastic chemotherapy is principally due to the inability of the drugs to differentiate between normal and malignant cells. This results in normal tissue...Keywords
This publication has 53 references indexed in Scilit:
- The current status of toxicity protectants in cancer therapy.1992
- Prevention of Cisplatin Neurotoxicity with an ACTH(4–9) Analogue in Patients with Ovarian CancerNew England Journal of Medicine, 1990
- Clinical trials of WR-2721 and cis-platinumInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1989
- UPTAKE OF WR-2721 DERIVATIVES BY CELLS IN CULTURE - IDENTIFICATION OF THE TRANSPORTED FORM OF THE DRUG1988
- Hypocalcemia and Inhibition of Parathyroid Hormone Secretion after Administration of WR-2721 (a Radioprotective and Chemoprotective Agent)New England Journal of Medicine, 1983
- Risk Factors for Doxorubicin-lnduced Congestive Heart FailureAnnals of Internal Medicine, 1979
- EFFECT OF DOXORUBICIN ON HEPATIC AND CARDIAC GLUTATHIONE1979
- CONTROLLED CLINICAL STUDIES WITH AN ANTIDOTE AGAINST THE UROTOXICITY OF OXAZAPHOSPHORINES - PRELIMINARY-RESULTS1979
- Generation of free radicals of quinone group-containing anti-cancer chemicals in NADPH-microsome system as evidenced by initiation of sulfite oxidation.1975
- Modification of some of the toxic effects of daunomycin (NSC-82,151) by pretreatment with the antineoplastic agent ICRF 159 (NSC-129,943)Toxicology and Applied Pharmacology, 1974